Antibody Testing in Pregnancy for Patients with Raynaud's Disease

Essential Antibody Panel

The American College of Rheumatology recommends testing for anti-Ro/SSA, anti-La/SSB, and antiphospholipid antibodies once before or early in pregnancy to assess risk for congenital heart block, neonatal lupus, and adverse pregnancy outcomes in patients with Raynaud's phenomenon 1
Testing for anti-Ro/SSA and anti-La/SSB antibodies once early in pregnancy assesses the risk of neonatal lupus and congenital heart block, which occurs in 0.7-2% of exposed fetuses 2
The presence of anti-Ro/SSA and anti-La/SSB antibodies predicts the need for serial fetal echocardiography from weeks 16-26 of gestation, with a strength of evidence supporting this recommendation 1, 3
If positive with no prior affected infant, serial fetal echocardiography should be performed; if there is a history of prior neonatal lupus, weekly fetal echocardiography is recommended 1, 4
Positive anti-Ro/SSA antibodies warrant consideration of hydroxychloroquine initiation if not already taking it, as this reduces congenital heart block risk, based on evidence from clinical guidelines 4

Testing for lupus anticoagulant, anticardiolipin, and anti-β2GPI antibodies once early in pregnancy predicts thrombotic events, preeclampsia, and pregnancy loss, with an odds ratio of 12.1 for thrombotic events and 2.3 for preeclampsia 1, 2
Positive antiphospholipid antibodies require anticoagulation strategies that significantly reduce pregnancy loss and other adverse outcomes, with a strength of evidence supporting this recommendation 1, 2
Treatment stratification for positive antiphospholipid antibodies includes low-dose aspirin alone for isolated positive aPL, low-dose aspirin plus prophylactic heparin for obstetric APS, or low-dose aspirin plus therapeutic heparin for thrombotic APS, based on clinical guidelines 1, 3

The presence of anti-Ro/SSA, anti-La/SSB, or antiphospholipid antibodies fundamentally changes pregnancy management, requiring specific monitoring protocols and prophylactic treatments, with a strength of evidence supporting this recommendation 1, 3
Positive anti-Ro/SSA or anti-La/SSB antibodies mandate intensive fetal cardiac surveillance to detect heart block early when intervention may prevent progression, based on evidence from clinical guidelines 4
Positive antiphospholipid antibodies require anticoagulation strategies that significantly reduce pregnancy loss and other adverse outcomes, with a strength of evidence supporting this recommendation 1, 2

If clinical suspicion for SLE exists, establishing baseline complement levels and anti-dsDNA antibody titers is recommended, with declining complement levels during pregnancy predicting disease flares and pregnancy loss 2
These tests help differentiate SLE flare from preeclampsia during pregnancy, with a strength of evidence supporting this recommendation 2